Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels

Journal of the American College of Cardiology

Volumn 40, Issue 1, 2002, Pages 49-55

  Blake, Gavin J ^a   Ridker, Paul M ^a   Kuntz, Karen M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; HYPERLIPIDEMIA; LIFE EXPECTANCY; MALE; MODEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE;

C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0037014641     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01914-9     Document Type: Article

References (39)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
2. High-sensitivity C-reactive protein (hs-CRP): A potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
3. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
4. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
5. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial
6. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
7. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
8. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
9. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
10. Long-term effects of pravastatin on plasma concentration of C-reactive protein
11. Effect of statins on C-reactive protein in patients with coronary artery disease
12. Reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
13. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
14. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
15. Markov models in medical decision making: A practical guide
16. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of the AFCAPS/TexCAPS
17. Coronary heart disease in residents of Rochester, Minnesota. VII. Incidence, 1950 through 1982
18. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
19. The multifactor primary prevention trial in Goteborg, Sweden
20. Effect of diet and smoking intervention on the incidence of coronary heart disease: Report from the Oslo Study Group of a randomised trial in healthy men
21. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
22. Test of effect of lipid lowering by diet on cardiovascular risk: The Minnesota Coronary Survey
23. Colestipol hydrochloride in hypercholesterolemic patients - Effect on serum cholesterol and mortality
24. The Lipid Research Clinics Coronary Primary Prevention trial results. I. Reduction in incidence of coronary heart disease
25. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: Report from the Committee of Principal Investigators
26. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results
27. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989
28. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials
29. Effect of HMGcoA reductase inhibitors on stroke: A meta-analysis of randomized, controlled trials
30. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
31. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
32. A randomised, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE)
33. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels
34. The cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults
35. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients
36. United States life tables, 1998
37. Gains in life expectancy from medical interventions - Standardizing data on outcomes
38. Expected gains in life expectancy from various coronary heart disease risk factor modifications